Search Results - "Kaplan, Richard S"

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial by Ledermann, Jonathan A, Prof, Embleton, Andrew C, MSc, Raja, Fharat, BMBCh, Perren, Timothy J, Prof, Jayson, Gordon C, Prof, Rustin, Gordon J S, Prof, Kaye, Stan B, Prof, Hirte, Hal, MD, Eisenhauer, Elizabeth, Prof, Vaughan, Michelle, MB, Friedlander, Michael, Prof, González-Martín, Antonio, MD, Stark, Daniel, MD, Clark, Elizabeth, BSc, Farrelly, Laura, MSc, Swart, Ann Marie, Prof, Cook, Adrian, MSc, Kaplan, Richard S, Prof, Parmar, Mahesh K B, Prof

“…Summary Background Angiogenesis is a validated clinical target in advanced epithelial ovarian cancer. Cediranib is an oral antiangiogenic vascular endothelial…”
Get full text

Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study by Brown, Louise Clare, Ahmed, Hashim U, Faria, Rita, El-Shater Bosaily, Ahmed, Gabe, Rhian, Kaplan, Richard S, Parmar, Mahesh, Collaco-Moraes, Yolanda, Ward, Katie, Hindley, Richard Graham, Freeman, Alex, Kirkham, Alexander, Oldroyd, Robert, Parker, Chris, Bott, Simon, Burns-Cox, Nick, Dudderidge, Tim, Ghei, Maneesh, Henderson, Alastair, Persad, Rajendra, Rosario, Derek J, Shergill, Iqbal, Winkler, Mathias, Soares, Marta, Spackman, Eldon, Sculpher, Mark, Emberton, Mark

“…Men with suspected prostate cancer usually undergo transrectal ultrasound (TRUS)-guided prostate biopsy. TRUS-guided biopsy can cause side effects and has…”
Get full text

Mind the gap? The platform trial as a working environment by Morrell, Liz, Hordern, Joshua, Brown, Louise, Sydes, Matthew R, Amos, Claire L, Kaplan, Richard S, Parmar, Mahesh K B, Maughan, Timothy S

“…Trials have become bigger and more complicated due to the complexity introduced by biomarker stratification, and the advent of multi-arm multi-stage trials,…”
Get full text

This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols by Schiavone, Francesca, Bathia, Riya, Letchemanan, Krishna, Masters, Lindsey, Amos, Claire, Bara, Anna, Brown, Louise, Gilson, Clare, Pugh, Cheryl, Atako, Nafisah, Hudson, Fleur, Parmar, Mahesh, Langley, Ruth, Kaplan, Richard S, Parker, Chris, Attard, Gert, Clarke, Noel W, Gillessen, Silke, James, Nicholas D, Maughan, Tim, Sydes, Matthew R

“…There are limited research and literature on the trial management challenges encountered in running adaptive platform trials. This trial design allows both (1)…”
Get full text

Phase II Multicenter Trial of Bevacizumab Plus Fluorouracil and Leucovorin in Patients With Advanced Refractory Colorectal Cancer: An NCI Treatment Referral Center Trial TRC-0301 by VAN CUTSEM, Eric, CHEN, Helen X, KAPLAN, Richard S, MOONEY, Margaret, BORON, Matthew, VENA, Don, MOSBY, Kiniberly, GROCHOW, Louise, JAFFE, Carl, RUBINSTEIN, Lawrence, ZWIEBEL, James

“…To provide bevacizumab (BV) -based therapy to patients with advanced colorectal cancers (CRC) who had exhausted standard chemotherapy options, and to evaluate…”
Get full text

Phase I Trial of Adenovirus-Mediated p53 Gene Therapy for Recurrent Glioma: Biological and Clinical Results by LANG, Frederick F, BRUNER, Janet M, CHANDLER, William, ZWIEBEL, James A, KAPLAN, Richard S, YUNG, W. K, FULLER, Gregory N, ALDAPE, Kenneth, PRADOS, Michael D, CHANG, Susan, BERGER, Mitchel S, MCDERMOTT, Michael W, KUNWAR, Sandeep M, JUNCK, Larry R

“…Advances in brain tumor biology indicate that transfer of p53 is an alternative therapy for human gliomas. Consequently, we undertook a phase I clinical trial…”
Get full text

Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed? by KORN, Edward L, ARBUCK, Susan G, PLUDA, James M, SIMON, Richard, KAPLAN, Richard S, CHRISTIAN, Michaele C

“…Preclinical data suggest that some new anticancer agents directed at novel targets demonstrate tumor growth inhibition but not tumor shrinkage. Such cytostatic…”
Get full text

Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials by TRIMBLE, Edward L, ABRAMS, Jeffrey S, SEIBEL, Nita, SHANKAR, Lalitha, SWART, Ann Marie, THERASSE, Patrick, VIKRAM, Bhadrasain, VON FRENCKELL, Remy, FRIEDLANDER, Michael, FUJIWARA, Keiichi, KAPLAN, Richard S, MEUNIER, Francoise, MEYER, Ralph M, CALVO, Fabien, CAZAP, Eduardo, DEYE, James, EISENHAUER, Elizabeth, FITZGERALD, Thomas J, LACOMBE, Denis, PARMAR, Max

“…The need for international collaboration in cancer clinical trials has grown stronger as we have made progress both in cancer treatment and screening. We…”
Get full text

What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort by Norris, Joseph M., Carmona Echeverria, Lina M., Bott, Simon R.J., Brown, Louise C., Burns-Cox, Nick, Dudderidge, Tim, El-Shater Bosaily, Ahmed, Frangou, Eleni, Freeman, Alex, Ghei, Maneesh, Henderson, Alastair, Hindley, Richard G., Kaplan, Richard S., Kirkham, Alex, Oldroyd, Robert, Parker, Chris, Persad, Raj, Punwani, Shonit, Rosario, Derek J., Shergill, Iqbal S., Stavrinides, Vasilis, Winkler, Mathias, Whitaker, Hayley C., Ahmed, Hashim U., Emberton, Mark

“…All risk stratification strategies in cancer overlook a spectrum of disease. The Prostate MR Imaging Study (PROMIS) provides a unique opportunity to explore…”
Get full text

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST) by Joffe, Johnathan K, Cafferty, Fay H, Murphy, Laura, Rustin, Gordon J S, Sohaib, Syed A, Gabe, Rhian, Stenning, Sally P, James, Elizabeth, Noor, Dipa, Wade, Simona, Schiavone, Francesca, Swift, Sarah, Dunwoodie, Elaine, Hall, Marcia, Sharma, Anand, Braybrooke, Jeremy, Shamash, Jonathan, Logue, John, Taylor, Henry H, Hennig, Ivo, White, Jeff, Rudman, Sarah, Worlding, Jane, Bloomfield, David, Faust, Guy, Glen, Hilary, Jones, Rachel, Seckl, Michael, MacDonald, Graham, Sreenivasan, Thiagarajan, Kumar, Satish, Protheroe, Andrew, Venkitaraman, Ramachandran, Mazhar, Danish, Coyle, Victoria, Highley, Martin, Geldart, Tom, Laing, Robert, Kaplan, Richard S, Huddart, Robert A

“…Survival in stage I seminoma is almost 100%. Computed tomography (CT) surveillance is an international standard of care, avoiding adjuvant therapy. In this…”
Get full text

High EMSY expression defines a BRCA‐like subgroup of high‐grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum by Hollis, Robert L., Churchman, Michael, Michie, Caroline O., Rye, Tzyvia, Knight, Laura, McCavigan, Andrena, Perren, Timothy, Williams, Alistair R. W., McCluggage, W. Glenn, Kaplan, Richard S., Jayson, Gordon C., Oza, Amit, Harkin, D. Paul, Herrington, C. Simon, Kennedy, Richard, Gourley, Charlie

“…Background Approximately half of high‐grade serous ovarian carcinomas (HGSOCs) demonstrate homologous recombination repair (HR) pathway defects, resulting in a…”
Get full text

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer by González Martín, Antonio, Oza, Amit M., Embleton, Andrew C., Pfisterer, Jacobus, Ledermann, Jonathan A., Pujade-Lauraine, Eric, Kristensen, Gunnar, Bertrand, Monique A., Beale, Philip, Cervantes, Andrés, Kent, Emma, Kaplan, Richard S., Parmar, Mahesh K.B., Scotto, Nana, Perren, Timothy J.

“…In the randomized phase 3 ICON7 trial (ISRCTN91273375), adding bevacizumab to chemotherapy for newly diagnosed ovarian cancer significantly improved…”
Get full text

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy by Madi, Ayman, Fisher, David, Maughan, Timothy S., Colley, James P., Meade, Angela M., Maynard, Julie, Humphreys, Vikki, Wasan, Harpreet, Adams, Richard A., Idziaszczyk, Shelley, Harris, Rebecca, Kaplan, Richard S., Cheadle, Jeremy P.

“…Inherited genetic variants may influence response to, and side-effects from, chemotherapy. We sought to generate a comprehensive inherited pharmacogenetic…”
Get full text

Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial by Stark, Dan P., Cook, Adrian, Brown, Julia M., Brundage, Michael D., Embleton, Andrew C., Kaplan, Richard S., Raja, Fharat A., Swart, Ann Marie W., Velikova, Galina, Qian, Wendi, Ledermann, Jonathan A.

“…BACKGROUND The ICON6 trial showed that cediranib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, improved clinical outcomes for…”
Get full text

In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer by Malla, Sudhir B, Fisher, David J, Domingo, Enric, Blake, Andrew, Hassanieh, Sylvana, Redmond, Keara L, Richman, Susan D, Youdell, Michael, Walker, Steven M, Logan, Gemma E, Chatzipli, Aikaterina, Amirkhah, Raheleh, Humphries, Matthew P, Craig, Stephanie G, McDermott, Ultan, Seymour, Matthew T, Morton, Dion G, Quirke, Philip, West, Nicholas P, Salto-Tellez, Manuel, Kennedy, Richard D, Johnston, Patrick G, Tomlinson, Ian, Koelzer, Viktor H, Campo, Letitia, Kaplan, Richard S, Longley, Daniel B, Lawler, Mark, Maughan, Timothy S, Brown, Louise C, Dunne, Philip D

“…The DNA damage immune response (DDIR) assay was developed in breast cancer based on biology associated with deficiencies in homologous recombination and…”
Get full text

False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS by Stavrinides, Vasilis, Syer, Tom, Hu, Yipeng, Giganti, Francesco, Freeman, Alex, Karapanagiotis, Solon, Bott, Simon R.J., Brown, Louise C., Burns-Cox, Nicholas, Dudderidge, Timothy J., Bosaily, Ahmed El-Shater, Frangou, Elena, Ghei, Maneesh, Henderson, Alastair, Hindley, Richard G., Kaplan, Richard S., Oldroyd, Robert, Parker, Chris, Persad, Raj, Rosario, Derek J., Shergill, Iqbal S., Echeverria, Lina M. Carmona, Norris, Joseph M., Winkler, Mathias, Barratt, Dean, Kirkham, Alex, Punwani, Shonit, Whitaker, Hayley C., Ahmed, Hashim U., Emberton, Mark

“…False positive multiparametric magnetic resonance imaging (mpMRI) phenotypes prompt unnecessary biopsies. The Prostate MRI Imaging Study (PROMIS) provides a…”
Get full text

Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial by Stavrinides, Vasilis, Norris, Joseph M, Karapanagiotis, Solon, Giganti, Francesco, Grey, Alistair, Trahearn, Nick, Freeman, Alex, Haider, Aiman, Carmona Echeverría, Lina María, Bott, Simon R J, Brown, Louise C, Burns-Cox, Nicholas, Dudderidge, Timothy J, El-Shater Bosaily, Ahmed, Ghei, Maneesh, Henderson, Alastair, Hindley, Richard G, Kaplan, Richard S, Oldroyd, Robert, Parker, Chris, Persad, Raj, Rosario, Derek J, Shergill, Iqbal S, Winkler, Mathias, Kirkham, Alex, Punwani, Shonit, Whitaker, Hayley C, Ahmed, Hashim U, Emberton, Mark

“…Background The effects of regional histopathologic changes on prostate MRI scans have not been accurately quantified in men with an elevated prostate-specific…”
Get full text

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group by Goey, Kaitlyn K.H., Sørbye, Halfdan, Glimelius, Bengt, Adams, Richard A., André, Thierry, Arnold, Dirk, Berlin, Jordan D., Bodoky, György, de Gramont, Aimery, Díaz-Rubio, Eduardo, Eng, Cathy, Falcone, Alfredo, Grothey, Axel, Heinemann, Volker, Hochster, Howard S., Kaplan, Richard S., Kopetz, Scott, Labianca, Roberto, Lieu, Christopher H., Meropol, Neal J., Price, Timothy J., Schilsky, Richard L., Schmoll, Hans-Joachim, Shacham-Shmueli, Einat, Shi, Qian, Sobrero, Alberto F., Souglakos, John, Van Cutsem, Eric, Zalcberg, John, van Oijen, Martijn G.H., Punt, Cornelis J.A., Koopman, Miriam

“…Patient characteristics and stratification factors are key features influencing trial outcomes. However, there is substantial heterogeneity in reporting of…”
Get full text

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab by Madi, Ayman, Fisher, David, Maughan, Timothy S, Colley, James P, Meade, Angela M, Tejpar, Sabine, Van den Bosch, Ben, Maynard, Julie, Humphreys, Vikki, Wasan, Harpreet, Adams, Richard A, Idziaszczyk, Shelley, Harris, Rebecca, Kaplan, Richard S, Cheadle, Jeremy P

“…Somatic mutations in the epidermal growth factor receptor (EGFR) intracellular signalling pathways predict non-response to cetuximab in the treatment of…”
Get more information

The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: A surveillance, epidemiology, and End Results analysis by OLSON, Janet E, JANNEY, Carol A, RAO, Ravi D, CERHAN, James R, KURTIN, Paul J, SCHIFF, David, KAPLAN, Richard S, O'NEILL, Brian Patrick

“…Primary central nervous system lymphoma (PCNSL) is an extranodal form of non-Hodgkin lymphoma arising in the craniospinal axis. The incidence of PCNSL appears…”
Get full text